EN | UA
EN | UA

Help Support

Back

BAT exhibits good diagnostic utility in patients with hypersensitivity to chemotherapeutics

Hypersensitivity reactions Hypersensitivity reactions
Hypersensitivity reactions Hypersensitivity reactions

What's new?

In people having hypersensitivity reactions to chemotherapeutics, the basophil activation test can aid to attain a better diagnosis.

Basophil activation test (BAT) is valuable for pheno-endotyping hypersensitivity reactions to chemotherapeutics in negative skin test allergic type-I people, particularly in those suffering from moderate/severe hypersensitivity reactions. This study sought to determine BAT utility in patients reporting immediate hypersensitivity reactions to taxanes and platinum compounds during 2020-2022.

Clinical history and skin tests (clinical phenotyping) were used to categorize patients into Type-I, Cytokine release reaction, or Mixed groups. As per Brown's classification, severity was determined. A total of 30 unaffected, non-exposed controls were also incorporated. Those who had mild- to moderately negative skin tests had a drug provocation test, and BAT was administered to all the participants.

In total, 90 patients were prospectively included. Out of these, 31 patients experienced reactions to taxanes (18 Docetaxel/13 Paclitaxel) and 59 patients experienced reactions to platins (30 Carboplatin/23 Oxaliplatin/6 Cisplatin). Finally, 65.4% of them were identified as allergic. Hypersensitivity reactions were consistent with Type-I in 37.1% of patients, cytokine release reaction in 41.3%, and mixed in 21.6% of participants.

The majority of patients (63%) experienced mild responses. In 55.3% of allergic people, BAT was positive, while it was negative in all non-allergic patients and controls. BAT specificity and sensitivity were 95.5% and 53.8% respectively, with an important association with skin test (r=0.7). Notably, 63% of moderate, 34% of severe, and 3% of mild hypersensitivity reactions were positive for BAT. In the study, 60% of Type-I, 30% Mixed, and 10% of individuals with cytokine release reaction tested positive for BAT.

Source:

Journal of Allergy and Clinical Immunology

Article:

Basophil activation test may help achieve a better diagnosis in patients with hypersensitivity reactions to chemotherapeutics

Authors:

GB Herrera et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: